These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9587036)

  • 41. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models.
    Wilson KM; Lentz SR
    Semin Vasc Med; 2005 May; 5(2):163-71. PubMed ID: 16047268
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Homocysteine and vascular disease.
    Hankey GJ; Eikelboom JW
    Lancet; 1999 Jul; 354(9176):407-13. PubMed ID: 10437885
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does tamoxifen enhance endothelial function by lowering the plasma levels of homocysteine?
    Cattaneo M
    Circulation; 2001 Dec; 104(24):E146-7. PubMed ID: 11739322
    [No Abstract]   [Full Text] [Related]  

  • 44. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.
    van Guldener C; Janssen MJ; Lambert J; ter Wee PM; Jakobs C; Donker AJ; Stehouwer CD
    Nephrol Dial Transplant; 1998 Jan; 13(1):106-12. PubMed ID: 9481724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis.
    Adams MR; Robinson J; McCredie R; Seale JP; Sorensen KE; Deanfield JE; Celermajer DS
    J Am Coll Cardiol; 1998 Jul; 32(1):123-7. PubMed ID: 9669259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic nature of endothelial dysfunction in atherosclerosis.
    Anderson TJ; Gerhard MD; Meredith IT; Charbonneau F; Delagrange D; Creager MA; Selwyn AP; Ganz P
    Am J Cardiol; 1995 Feb; 75(6):71B-74B. PubMed ID: 7863979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Endothelium-derived factors and peripheral vascular disease.
    Cooke JP
    Cardiovasc Clin; 1992; 22(3):3-17. PubMed ID: 1600550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low risk of thrombosis in family members of patients with hyperhomocysteinaemia.
    Martinelli I; Bucciarelli P; Zighetti ML; Cafro A; Mannucci PM
    Br J Haematol; 2002 Jun; 117(3):709-11. PubMed ID: 12028046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients.
    Schlaich MP; John S; Jacobi J; Lackner KJ; Schmieder RE
    Atherosclerosis; 2000 Dec; 153(2):383-9. PubMed ID: 11164427
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reversible hypertension following coeliac disease treatment: the role of moderate hyperhomocysteinaemia and vascular endothelial dysfunction.
    Lim PO; Tzemos N; Farquharson CA; Anderson JE; Deegan P; MacWalter RS; Struthers AD; MacDonald TM
    J Hum Hypertens; 2002 Jun; 16(6):411-5. PubMed ID: 12037696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Can lowering homocysteine levels reduce the incidence of stroke?
    Sarkar PK; Lambert L
    J Clin Pharm Ther; 1999 Oct; 24(5):331-8. PubMed ID: 10583695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Markers of platelet activation and oxidant stress in atherothrombotic disease.
    FitzGerald GA; Tigges J; Barry P; Lawson JA
    Thromb Haemost; 1997 Jul; 78(1):280-4. PubMed ID: 9198167
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease.
    Stanger O; Weger M; Renner W; Konetschny R
    Clin Chem Lab Med; 2001 Aug; 39(8):725-33. PubMed ID: 11592442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperhomocysteinaemia and end stage renal disease.
    Gupta A; Robinson K
    J Nephrol; 1997; 10(2):77-84. PubMed ID: 9238614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of nitric oxide and other endothelium-derived factors].
    Stankevicius E; Kevelaitis E; Vainorius E; Simonsen U
    Medicina (Kaunas); 2003; 39(4):333-41. PubMed ID: 12738901
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The case for mild hyperhomocysteinaemia as a risk factor.
    Boers GH
    J Inherit Metab Dis; 1997 Jun; 20(2):301-6. PubMed ID: 9211202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Putative mechanisms for vascular damage by homocysteine.
    Bellamy MF; McDowell IF
    J Inherit Metab Dis; 1997 Jun; 20(2):307-15. PubMed ID: 9211203
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.
    Tsai JC; Perrella MA; Yoshizumi M; Hsieh CM; Haber E; Schlegel R; Lee ME
    Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6369-73. PubMed ID: 8022789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications.
    Blann AD; Lip GY
    Blood Coagul Fibrinolysis; 1998 Jun; 9(4):297-306. PubMed ID: 9690800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases.
    Oussalah A; Guéant JL; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1173-84. PubMed ID: 21967576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.